During the past decade, Providence Multiple Sclerosis Center conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Multiple Sclerosis Center" #1 sponsor was "Providence Health & Services" with 4 trials, followed by "Opexa Therapeutics, Inc." with 3 trials sponsored, "Sanofi" with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Acorda Therapeutics" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Multiple Sclerosis Center" #1 collaborator was "Autoimmunity Centers of Excellence" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Microstein, LLC" with 1 trials as a collaborator and "Multiple Sclerosis Center of Northeastern New York" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Providence Multiple Sclerosis Center" are "Multiple Sclerosis" (6 trials), "Multiple Sclerosis, Relapsing-Remitting" (3 trials), "Secondary Progressive Multiple Sclerosis" (3 trials), "Clinically Isolated Syndrome" (2 trials) and "Relapsing Remitting Multiple Sclerosis" (2 trials). Many other conditions were trialed in "Providence Multiple Sclerosis Center" in a lesser frequency.

Most popular intervention types in "Providence Multiple Sclerosis Center" are "Drug" (10 trials), "Biological" (3 trials), "Procedure" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Tolebrutinib" (3 trials), "Blood Draw" (2 trials), "Ocrelizumab" (2 trials) and "Placebo to match Tolebrutinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Providence Multiple Sclerosis Center" are 16 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Providence Multiple Sclerosis Center". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Providence Multiple Sclerosis Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Multiple Sclerosis Center, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".